Overview

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

Status:
Recruiting
Trial end date:
2028-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Sacramento Pediatric Gastroenterology
Treatments:
Vancomycin
Criteria
Inclusion Criteria:

- Persons who have primary sclerosing cholangitis, biliary atresia, a chronic intestinal
disorder or who are undergoing upper or lower endoscopy.

- Persons who have primary sclerosing cholangitis or biliary atresia who are good
candidates for vancomycin therapy.

Exclusion Criteria:

- Patients that have taken antibiotics and/or immunomodulators within the last 3 months
will be excluded as this will alter the original bacterial flora.

- Females who are pregnant may not participate.